Table 4 Lifetime cost (USD) of each dialysis modality strategy as first-line treatment and incremental cost-effectiveness ratio in base-case scenario
Perspective | Strategy | Cost (USD) | Incremental Cost (USD) | Effectiveness (QALY) | Incremental Effectiveness | ICER (USD / QALY gained) |
|---|---|---|---|---|---|---|
Healthcare provider | ||||||
PDa | 76,915 | NA | 7.13 | NA | NA | |
Home-based HD | 97,917 | 21,002 | 8.37 | 1.24 | 16,934 | |
Hospital-based HD | 142,389 | 44,472 | 6.58 | Dominated by PD | ||
Societal | ||||||
PDa | 109,668 | NA | 7.13 | NA | NA | |
Home-based HD | 111,150 | 1482 | 8.37 | 1.24 | 1195 | |
Hospital-based HD | 166,648 | 56,980 | 6.58 | Dominated by PD | ||